Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.68

-2.4%

Dec 12 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who started this subject	5/6/2002 3:29:27 PM
From: johnsto1	of 52153

[$50 target these days is about as strong as I have seen] 05 May 2002, 12:20 PM EDT Msg. 7295 of 7295 Robby Steven's upgrades Target $50 on HGSI Human Genome (HGSI) 15.86 +0.12: HGSI provided a detailed overview of the product pipeline and clinical development strategy at its annual analyst meeting yesterday; firm maintained its goal of filing 3-4 new product INDs per year, 2 of which have already been filed in 2002 (LymphoRad & TRAIL R1 monoclonal antibody). Goldman Sachs expects a third IND for Albugranin, albumin-fusion G-CSF, to be filed in Q2/Q3 and reiterates their Mkt Outperform rating. Robertson Stephens believes the initial activity of these compounds represents just the tip of a large and valuable product pipeline and rates the shares a Strong Buy with a $50 price target.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next